RVRC · Revium Rx.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 9, 2020; bars on opposite sides are not compared.
The closing range uses available history since Jan 5, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVRC
this stock
Revium Rx.
|
$86.84M | — | — | — | — |
|
VEEV
Veeva Systems Inc
|
$45.40B | +25.8% | +28.1% | 45.9 | 3.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.25B | -29.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.92B | +60.9% | +28.2% | 36.5 | 4.5% |
|
TEM
Tempus AI, Inc.
|
$11.14B | +4.9% | +83.4% | — | 16.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 9, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVRC | +256.5% | -42.8% | — | -14.4% | +175.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +257.9% | -46.4% | — | -16.9% | +162.7% |